Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 72,018 |
|
|||||
| News | - | ||||||
| Day High | 2.24 | Low High |
|||||
| Day Low | 1.97 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Entera Bio Ltd | ENTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.11 | 5.37% | 2.16 | 14:18:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.05 | 1.97 | 2.24 | 2.05 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 321 | 72,018 | $ 2.10 | $ 151,056 | - | 0.52 - 3.35 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:21:24 | 9 | $ 2.16 | USD |
Entera Bio Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 76.64M | 35.48M | - | 49k | -8.89M | -0.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Entera Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ENTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.4202 | 2.4202 | 1.8101 | 2.17 | 266,941 | -0.2602 | -10.75% |
| 1 Month | 1.75 | 3.35 | 1.45 | 2.35 | 427,393 | 0.41 | 23.43% |
| 3 Months | 0.88 | 3.35 | 0.6801 | 1.95 | 237,464 | 1.28 | 145.45% |
| 6 Months | 0.6817 | 3.35 | 0.52 | 1.65 | 149,741 | 1.48 | 216.85% |
| 1 Year | 0.831 | 3.35 | 0.52 | 1.47 | 93,511 | 1.33 | 159.93% |
| 3 Years | 3.07 | 8.68 | 0.4722 | 5.10 | 366,787 | -0.91 | -29.64% |
| 5 Years | 4.02 | 10.16 | 0.4722 | 4.54 | 705,354 | -1.86 | -46.27% |
Entera Bio Description
| Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The company's product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in clinical development. The company recently completed the phase 2 study for EB613. The company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. |
